Publications by authors named "Blake Morrison"
Article Synopsis
- Lung cancer cells, particularly NSCLC, increase their ability to survive oxidative stress by upregulating the xCT transporter for cystine, which helps maintain high intracellular cysteine levels necessary for making glutathione.* -
- The NRF2 transcription factor regulates the xCT transporter and is kept in check by KEAP1; mutations in KEAP1 or NRF2 can enhance cystine uptake and support cancer cell survival, while limited cystine can lead to ferroptosis, a form of cell death.* -
- Targeted therapies in certain NSCLC types can trigger pyroptosis and apoptosis, leading to the breakdown of the cell membrane after caspase-3 activation, contributing to death of the cancer cells.*
Bortezomib synergizes with melphalan in preclinical and early clinical studies. Updated data from our phase 1/2 study assessing the safety and efficacy of bortezomib plus melphalan in relapsed/refractory multiple myeloma (MM) are presented. Bortezomib (0.
View Article and Find Full Text PDFPurpose: This multicenter, open-label, phase I/II dose escalation study assessed the safety/tolerability and initial efficacy of arsenic trioxide/bortezomib/ascorbic acid (ABC) combination therapy in patients with relapsed/refractory multiple myeloma.
Experimental Design: Enrolled in six cohorts, patients were given arsenic trioxide (0.125 or 0.
Purpose: Bortezomib has shown synergy with melphalan in preclinical models. We assessed the safety, tolerability, and response rate in a dose-escalation study of this combination for relapsed or refractory multiple myeloma patients.
Methods: Bortezomib was administered from 0.